London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Corneal morphology and aberrometric variation in epi off collagenic cross linking

Poster Details

First Author: A.Rampone ITALY

Co Author(s):    E. Paolillo   A. Orrico   M. Bifani   M. Lanza   S. Sbordone  

Abstract Details

Purpose:

to evaluate the corneal morphological and aberrometric variations in patients affected by keratoconus (KC) that underwent corneal collagen cross-linking (CXL) with epithelial removal.

Setting:

Retrospective study performed in Seconda Università degli studi di Napoli, Naples.

Methods:

seventeen eyes of 17 KC patients with a mean age of 25.52 ± 7.35 years ( from 15 to 41 years ) were included in this study; they were affected by KC grade 2 according with Krumeich classification. Best corrected visual acuity (BCVA), corneal power, central corneal thickness (CCT), corneal thinnest point (CTP) and corneal aberrations were measured in all eyes before undergoing CXL (epi off ) and at 1, 3 and 6 months follow up. Corneal parameters have been evaluated with Pentacam HR (Oculus). Differences have been verified with Student T test.

Results:

At 6 months follow up, BCVA showed a not significant (p>0.05) changes (0.9 ± 0,15); corneal power, flattest meridian and steepest meridian showed a significant (p<0.05) reduction (-1.44 ± 2,92 diopters (D), -1.66 ± 0.86 D and 1.21 ± 0.86 D respectively); high order aberrations (HOA) showed a not significant (p<0.05) variation.

Conclusions:

even if these data should be confirmed in further study with larger population and longer follow up, our results suggest that CXL (epi-off) is effective in improving corneal curvature without worsening BCVA and corneal aberrations in eyes affected by KC at earlier stages.

Financial Disclosure:

NONE

Back to Poster listing